Failed regeneration of CNS myelin contributes to clinical decline in neuroinflammatory and neurodegenerative diseases, for which there is an unmet therapeutic need. Here we reveal that efficient remyelination requires death of proinflammatory microglia followed by repopulation to a proregenerative state. We propose that impaired microglia death and/or repopulation may underpin dysregulated microglia activation in neurological diseases, and we reveal therapeutic targets to promote white matter regeneration.
CNS remyelination reinstates axon health/function 1 , yet fails in prevalent neurodegenerative disorders contributing to axon dysfunction/loss for which there is an unmet therapeutic need. These disorders (for example, multiple sclerosis, amyotrophic lateral sclerosis (ALS), spinal cord injury) are associated with chronic activation of resident immune cells, microglia [2] [3] [4] . Resolution of proinflammatory microglia activation (iNOS + TNFα + CCL2 + ) via a transition to a proregenerative microglia state (Arg-1 + CD206 + IGF-1 + ) initiates remyelination 3 . Remyelination is impaired when this transition is prevented (by depletion of pro-regenerative microglia), or when it fails, identified by prolonged proinflammatory microglia presence in aged mice and chronic human brain lesions 3 . However, the mechanisms underpinning this transition in microglia activation remain unknown.
To reveal these mechanisms, we performed RNA sequencing of microglia isolated from focal demyelinated lesions of young adult mouse corpus callosum induced with the myelin toxin lysophosphatidyl choline (LPC), where regeneration occurs without concomitant damage and timing of microglia activation is defined (Fig. 1a ) 3 . At peak proinflammatory (3 d post-LPC (dpl)) and pro-regenerative microglia activation (10 dpl), microglia were isolated by fluorescence-activated cell sorting (FACS) based on expression of CD11b, lack of expression of neutrophil/T-lymphocyte markers (Ly6G, CD3) and low expression of CD45 (gating strategy in Supplementary  Fig. 1a ). Cells expressed microglia signature genes post-demyelination ( Supplementary Fig. 1b) ; we assessed regulation of two of these genes (P2ry12, Csf1r) after demyelination versus non-lesion microglia, and observed no significant change at 3 dpl yet upregulation at 10 dpl ( Supplementary Fig. 1c ). Cells did not express markers for border-associated macrophages or monocyte-derived cells ( Supplementary Fig. 1d ). Of the 5,000 most highly expressed genes (including non-differentially expressed genes), 57.2% were shared and 21.4% were specific to each time point (Fig. 1b) . Microglia expressed genes associated with microglia during developmental myelination 5, 6 or neurodegeneration 7, 8 (Supplementary Fig. 1e -i), some of which were significantly enriched at 10 dpl. A total of 1,020 genes were significantly differentially expressed between 3 and 10 dpl (P < 0.05) ( Fig. 1c ; log 2 fold change in Supplementary  Table 1) , including genes involved in survival/proliferation (Birc5, Smad2, Ccnb1), anti-oxidant responses (Keap1), inflammation (Tnfrsf1b, Jak2, Nfkbid, Cryba1, Gpmnb, Socs1, Cd40) and remyelination (Axl, Osm, Adam8), and associated with microglia in neurodegeneration (Msr1, Hdac5, Syp) ( Supplementary Fig. 1j ). Pathway analysis identified enrichment of chronic inflammation at 3 dpl, and anti-inflammatory responses/transcriptional regulators at 10 dpl (Supplementary Figs. 1k and 2 and Supplementary Table 2 ). Significantly upregulated genes at 10 dpl included those encoding proteins associated with remyelination/regeneration (Matn2, Osm, Fgf1, Cd300lf), myelination (Bmp1, Cd69, Fabp5) and oligodendrocyte lineage responses (iron export (Cp), Wnt pathway inhibition (Nit1)) ( Fig. 1d and Supplementary Fig. 1l ). Microglia at both time points showed engagement of phagocytic pathways, by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis ('fat digestion' at 3 dpl; 'endocytosis' at 10 dpl; Fig. 1e ), Gene Ontology enrichment (for example, 'degradation of lipoproteins' at 3 dpl; 'structural constituent of myelin sheath' at 10 dpl; Supplementary Fig. 2 ) and receptor expression (Fig. 1f) , suggesting engulfment/breakdown of myelin debris throughout remyelination.
Cell death-associated pathways were enriched in microglia at 3 dpl, with (1) engagement of KEGG pathways ('axon guidance' , 'colorectal cancer') associated with genes regulating cell death (Birc5, Smad2, Ephrb1/2) (Fig. 1e) , (2) 'cell death & survival' identified as a major molecular and cellular function (Fig. 1g) due to regulation of genes associated with death (for example, TNF receptor signaling, TRAIL, p53; Supplementary Table 3) , and (3) most transcriptional regulators upregulated at 3 dpl known to control cell death (Supplementary Table 2 and Supplementary Fig. 1m ). To determine whether microglia undergo death after demyelination, we analyzed IBA-1 + cells in lesions, which were homogenous at 3 dpl, sparse at 7 dpl and clustered at 10 dpl ( Red represents higher expression and blue represents lower expression. d, Genes with a significant log 2 fold change (P < 0.05) in 10-dpl versus 3-dpl microglia with known roles in regulating remyelination, myelination and the oligodendrocyte lineage, represented as mean FPKM (± s.e.m.). *P = 0.0174 (two-tailed paired Student's t test, t = 2.988, d.f. = 9) . N = 3 mice per time point. e, KEGG pathways engaged in genes significantly differentially expressed (P < 0.01) by microglia at 3 versus 10 dpl. KEGG pathways are represented on the y axis, and enrichment score on the x axis is represented as -log 10 (P) enrichment (P < 0.05, right-tailed Fisher's exact test performed for upregulated and downregulated genes separately). f, Expression of genes associated with phagocytosis of myelin debris in microglia at 3 and 10 dpl, indicated as mean FPKM (± s.e.m.). No significance between time points, two-tailed paired t test (P = 0.0690, t = 2.037, d.f. = 10). N = 3 mice per time point. g, IPA of significantly engaged molecular and cellular functions in microglia (P < 0.05, right-tailed Fisher's exact test), indicating 'cell death & survival' as a key pathway. h, Mean density of IBA-1 + cells per mm 2 (± s.e.m.) of lesioned corpus callosum at 3, 7 and 10 dpl. *P = 0.0486 for 3 dpl (t = 4.371, d.f. = 2), P = 0.0899 for 7 dpl (t = 4.371, d.f. = 2), *P = 0.011 for 10 dpl (t = 4.371, d.f. = 2) (two-tailed one-sample t test compared with average density in sham-injected mice; indicated by the dotted line). N = 3 mice per time point. i, Representative images of lesions in the corpus callosum stained for IBA-1 (green) and counterstained with Hoechst (blue). Scale bar, 50 µm. The experiment was performed with three mice per time point. j, Flow cytometry plots of lesion-isolated microglia (CD11b-PeCy7 + CD45-BV605 lo ) positive for cell death markers Annexin-V-FITC and 7-AAD at 3, 7 and 10 dpl. The experiment was performed with three mice per time point. k, Mean proportion of all microglia that are Annexin-V +
7-AAD
+ at 3, 7 and 10 dpl ± s.e.m. ****P < 0.0001 3 dpl versus 7 dpl (t = 20.21, d.f. = 4), *P = 0.0233 7 dpl versus 10 dpl (t = 3.161, d.f. = 4). Two-tailed unpaired Student's t test. N = 3 mice per time point.
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Nature NeuroSCieNCe 7 dpl (Fig. 1h,i) . Flow cytometric analysis of microglia (CD11b + CD45 lo ) revealed an increase in death (Annexin-V + 7-AAD + ) at 7 dpl ( Fig. 1j,k ; gating strategy, Supplementary Fig. 3a,c) . Microglia isolated from sham-lesioned mice at 7 d post-surgery were negative for Annexin-V and 7-AAD ( Supplementary Fig. 3b ), excluding that death occurred from injection/cell isolation. Thus, after demyelination and before onset of remyelination, microglia die during the transition from proinflammatory to pro-regenerative activation.
To investigate mechanisms regulating microglia death after demyelination, we first used ex vivo mouse organotypic cerebellar explants which mimic in vivo tissue microenvironments and remyelination ( Supplementary Fig. 4a) Fig. 4g-i) . Live incorporation of a marker of compromised membrane integrity (propidium iodide) confirmed microglia death before cell loss (18-24 h post-LPC (hpl)) and propidium iodide was present in most PU.1 + microglia nuclei by 24 hpl ( Supplementary Fig. 4j-m) . LPC did not have toxic effects on microglia as no cell loss occurred when primary microglia were treated overnight ( Supplementary Fig. 5a ). Live imaging of explants from microglia reporter mice (Csf1r-eGFP) showed microglia rounding up and rupturing post-LPC, which was not observed in control (Supplementary Videos 1 and 2). Microglia were negative for apoptotic markers (cleaved caspase-3, TdT-mediated dUTP nick end labeling), and constitutively positive for pyroptosis marker cleaved caspase-1 even without demyelination ( Supplementary  Fig. 5b,c) . We then investigated necroptosis, a programmed necrosis whereby a necroptosome complex composed of RIPK1, RIPK3 and MLKL compromises membrane integrity. Necroptosis markers were expressed in IBA-1 + or CD68 + cells after demyelination before death: at 3 dpl in vivo (Fig. 2a-c and Supplementary Fig. 5d ; IBA-1 and MLKL co-localization: 34.2% at 3 dpl versus 7.0% at 7 dpl) and 12 hpl in explants (Fig. 2d,e) . CD68
+ cells in shaminjected mice were RIPK3-negative (Fig. 2a) 
, and CD68 strongly co-localized with microglial marker Tmem119 (Supplementary Fig. 6 ). We confirmed that microglia necroptosis is a common feature of remyelination by analyzing two additional in vivo demyelination models. In the cuprizone toxin-diet model, RIPK3
+ and MLKL + microglia were significantly increased at remyelination onset and decreased when complete ( Supplementary Fig. 7a-d) . Mining of published microglia transcriptomes from a model of chronic myelin injury to the spinal cord (MOG-induced experimental autoimmune encephalomyelitis) 9 indicated expression of Ripk3 and Mlkl at late stages of disease when remyelination occurs 10 ( Supplementary Fig. 7e ). Therefore, microglia necroptosis is associated with remyelination, regardless of CNS region or mode of injury.
To determine the role of microglia necroptosis in remyelination, we used necrostatin-1, a small molecule which prevents necroptosome activity. At 1 dpl, necrostatin-1 treatment of demyelinated explants prevented loss of CD68 + microglia (Fig. 2f ) and maintained iNOS + CD68 + microglia (Fig. 2g-h ), even at 7 dpl when the transition to the pro-regenerative phenotype would normally have taken place (Fig. 2g,h ). We observed a decrease in iNOS + CD68 + cell numbers by 14 dpl (Fig. 2g) , indicating either delayed change in activation or apoptosis due to prolonged necroptosis inhibition. Necrostatin-1 significantly hindered remyelination at 7 and 14 dpl compared with vehicle control (Fig. 2i,j) . This did not result from directly 
Nature NeuroSCieNCe inhibiting oligodendrocyte or neuronal necroptosis 11, 12 , as only ~3% of oligodendrocyte lineage cells (Olig2 + ) or neurons (NeuN
+ post-LPC in explants (Supplementary Fig. 8a-d ). Necrostatin-1 treatment of undemyelinated explants had no consequence on MBP immunoreactivity or iNOS expression in CD68 + microglia ( Supplementary Fig. 8e ,f). To determine whether microglia necroptosis is required for remyelination in vivo, we aimed to target necrostatin to macrophages by encapsulation in lipidic nanocapsules (LNCs), predicted to be preferentially taken up by phagocytes as shown with other lipid-rich nanoparticle formulations (Fig. 2k ). Uptake specificity in lesions was verified by injection of 1,1′-dioctadecyl-3,3,3′,3′ tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD)-labeled LNCs, with >90% of DiD clusters co-localized with IBA-1 + cells (Fig. 2l, Fig. 2n and Supplementary Fig. 8g,h) ). Threedimensional (3D) reconstruction confirmed internalization of DiD LNCs within IBA-1 + cells ( Fig. 2m and Supplementary Fig. 8h ). At 3 dpl, necrostatin-loaded LNCs inhibited microglia necroptosis as indicated by decreased MLKL in IBA-1 + cells compared with vehicle (dimethylsulfoxide)-LNCs (Fig. 2o) Fig. 8i ), as expected given that necrostatin does not prevent RIPK3 expression but acts downstream to inhibit MLKL recruitment/activation. Necrostatin-LNCs caused a relative increase in Tmem119 + cells compared with vehicle-LNCs, associated with increased percentage of CD68
+ cells expressing iNOS and decreased percentage of those expressing Arg-1 (Fig. 2p) . Increased microglia numbers were not due to proliferation, as Ki67 + PU.1 + cell number was significantly downregulated at 3 dpl in Necrostatin-LNC-treated lesions relative to vehicle-LNC control, then negligible by 10 dpl (Supplementary Fig. 8j ). Remyelination was impaired at 10 dpl following necrostatin-LNC treatment, as indicated by reduced expression of early remyelination marker myelin-associated glycoprotein (MAG) (Fig. 2q,r) . This was not due to accumulation of myelin debris (identified using MBP which is not yet expressed at this early stage of remyelination) which was equally cleared in both conditions ( Supplementary Fig. 8k ), consistent with RNA sequencing data suggesting phagocytic capacity of proinflammatory microglia (Fig. 1e,f and Supplementary Fig. 2 ). Altogether, these data demonstrate the requirement for microglia necroptosis for remyelination to occur, although we acknowledge the possibility that inhibiting necroptosis of a small percentage of other cell types may have also affected remyelination.
We next determined how microglia repopulate to the pro-regenerative phenotype following demyelination. We assessed Nestin expression, which identifies repopulating microglia following experimental depletion [13] [14] [15] . In vivo lesions showed increased co-localization of IBA-1 with Nestin from 3 dpl to 7 dpl, which was reduced by 10 dpl when the transition in microglia activation has taken place ( Fig. 3a-c) . Little to no Nestin was co-localized with IBA-1 in sham control, indicating expression by microglia largely during remyelination (Fig. 3a) . Microglia repopulation following experimental depletion has been proposed to occur via: (1) de novo differentiation of CNS-resident Nestin + cells 14 , or (2) proliferation of residual microglia which did not die 13, 15 . However, these studies examined microglia repopulation in healthy gray matter, where the microenvironment may differ from injured white matter. To investigate microglia repopulation following demyelination, we induced focal lesions in mice in which Nestin promoter-driven tdTomato (tdT) expression is inducible (Nes-CreERT2;RCL-tdT), allowing labeling of Nestin + cells before demyelination. Of all tdT + cells, the proportion that were CD11b + CD45 lo (gating, Supplementary Fig. 9a ) increased from 3 dpl to 7 and 10 dpl (Fig. 3d,e and Supplementary  Fig. 9b ). Although the proportion of all CD11b
+ CD45 lo cells that were tdT + increased at 7 dpl versus 3 dpl and sham control, these only represented <5% of total microglia (Fig. 3f,g ), suggesting that repopulation in vivo is mediated primarily by residual microglia.
Microglia repopulation also occurred in the explant model ( Supplementary Fig. 4c ). Recombination in Nestin + cells before LPC led to detection of some tdT + IBA-1 + cells only during early repopulation (1-2 dpl), which were undetectable by 7 dpl (Supplementary The experiment was performed on four active lesions and three control tissues. m, In vivo remyelinating lesions at 3, 7 and 10 dpl immunostained for CD68 (red) and IFNAR2 (green), counterstained with Hoechst (blue). Inset: rabbit primary isotype control. Scale bar, 10 μm. The experiment was performed on three mice per time point. n, In vivo remyelinating lesions at 3, 7 and 10 dpl immunostained for PU.1 (red) and P-Y701 (green), counterstained with Hoechst (blue). Scale bar, 25 μm. The experiment was performed on three mice per time point. o, Representative image of focal in vivo lesion at 7 dpl immunostained for PU.1 (red) and P-Y701 (green), counterstained with Hoechst (blue). White square corresponds to panel n. 
Nature NeuroSCieNCe Fig. 9c-f) ; tdT + cells expressed neural stem cell markers Musashi-1 and Sox-2, but not GFAP (Supplementary Fig. 9g ). We assessed the contribution of residual microglia to repopulation in explants derived from Cx3cr1-CreER;RCL-tdT mice ( Supplementary Fig. 9h ), in which tdT labeled IBA-1 + microglia ( Supplementary Fig. 9i ) but not the oligodendrocyte lineage, previously suggested to express CX3CR1 (Supplementary Fig. 9j ). The majority of repopulated IBA-1 + cells were tdT + and therefore derived from residual microglia ( Supplementary Fig. 9k-m) , with 30% being Nestin + at 2 dpl ( Supplementary Fig. 9n,o) . Therefore, lineage tracing supports that microglia repopulation during remyelination occurs primarily from residual microglia. 
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To investigate necroptosis and repopulation in human white matter disease, we examined multiple sclerosis lesion subtypes: (1) active lesions, which have high densities of macrophages, positively correlated with remyelination and oligodendrocyte precursor abundance; (2) chronic inactive lesions, which have low potential for remyelination; and (3) fully remyelinated lesions (Supplementary Table 4 Fig. 3j,l) were present in all multiple sclerosis lesion types, these were only significantly increased in active lesions compared with control. This may suggest abundance of cues for pro-remyelination microglial responses in an inflammatory environment.
We next investigated molecular pathways controlling microglia during remyelination. IPA analysis indicated regulation of type-1 interferon (IFN) signaling, with 'Interferon signaling' and 'Role of JAK1, JAK2 and TYK2 signaling in Interferon signaling' identified as top canonical pathways, and top predicted upstream regulators included IFNα/β, IFNAR, STAT1, IRF7 and IRF3 (P = 0.00013, 0.00089, 0.000045, 0.0071 and 0.000086, respectively). Microglia expressed genes encoding the IFNα/β receptor (Ifnar1, Ifnar2) and IFN-associated genes linked with microglia during remyelination 16 ( Supplementary Fig. 10a,b) , and CD68
+ cells expressed IFNα/β receptor subunit 2 (IFNAR2) protein in vivo (Fig. 3m) . IFN signaling, assessed by nuclear phospho-STAT1 (P-Y701), was only active at 7 dpl in vivo and was selective to 58 ± 7% of PU.1 + nuclei (Fig. 3n,o) , consistent with the largest microglia subpopulation in this model having an IFN signature 16 . We assessed the role of type-1 IFN signaling using explants where microglia death and repopulation are temporally separated and can be investigated in isolation. Using a neutralizing antibody against IFNAR2 did not significantly affect PU.1 + microglia numbers at 1 dpl compared with IgG isotype control (Fig. 3p) , therefore did not prevent microglia death. A significant increase in PU.1 + cells was observed from 1 dpl to 7 dpl in controls but not following IFNAR2 blockade (Fig. 3p) , suggesting impaired microglia repopulation. PU.1 + cells were significantly reduced in anti-IFNAR2 IgG conditions relative to control at 7 dpl (Fig. 3p,q) , associated with decreased P-Y701 + PU.1 + microglia (Supplementary Fig. 10c ). Consequently, blocking IFNAR2 impaired early remyelination at 7 dpl relative to control (Fig. 3r,s) . Altogether, these data support a regenerative role for type-1 IFN signaling in regulating the repopulation of white matter microglia during efficient remyelination.
In summary, our data reveal that remyelination is driven by proinflammatory microglia necroptosis and repopulation to a regenerative state. Whereas necroptosis of other cell types 11, 12 is associated with demyelination and neurodegeneration, we show a regenerative role for necroptosis in shutting down proinflammatory microglial activation to support remyelination. Although previous studies identified the capacity of microglia to repopulate following experimental depletion in healthy [13] [14] [15] , aged 17 , irradiated 18 or neurodegenerating brain 19 , we show that this feature can also serve to reinstate microglia after naturally occurring death following white matter injury, while regulating microglia activation. We reveal that microglia repopulation during white matter remyelination is positively regulated by type-1 IFN signaling. This contrasts with its deleterious role in repopulated microglia selectively in gray matter following experimental depletion 20 , highlighting CNS region-specific consequences of IFN signaling in microglia. We propose that targeting proinflammatory microglia death may represent a strategy to dampen chronic CNS white matter inflammation, and support a regenerative response to reinstate myelin integrity.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41593-019-0418-z. tm9(CAG-tdTomato)Hze /J) were crossed with C57Bl6-Tg(Nes-CreERT2) KEisc/J to induce tdT expression in Nestin + cells, or crossed to Cx3cr1-CreER to induce tdT expression in microglia. Recombination in vivo was induced by two subcutaneous injections of tamoxifen (2 mg in 200 µl corn oil; Sigma-Aldrich, T5648) 48 h apart, 5-7 d before brain lesioning. Recombination in explants was induced by overnight treatment with 1 µM 4-hydroxy-tamoxifen (SigmaAldrich), followed by three washes and an additional three media changes over the course of the subsequent week, before demyelination. For live imaging, MacGreen mice (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J) were used. Sprague-Dawley rats were used for primary microglial cultures. All animals were purchased from Jackson Laboratories.
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Organotypic cerebellar explant cultures. Cerebellum and hindbrain were isolated from postnatal day (P) 0-P2 CD1 mouse pups of both sexes and sectioned sagittally at 300 μm on a McIlwain tissue chopper. Explants were plated onto Millipore-Millicell-CM mesh inserts (Fisher Scientific) in six-well culture plates at six explants per insert for immunofluorescence or three explants per insert for live imaging. Explant culture medium consisted of 50% minimal essential medium, 25% heat-inactivated horse serum, 25% Earle's balanced salt solution (all from GIBCO), 6.5 mg ml −1 glucose (Sigma-Aldrich), 1% penicillin-streptomycin (Life Technologies), 1% Glutamax (Life Technologies) and 1% HEPES (Invitrogen), and was changed every 2-3 d. Demyelination was induced at 21 d in vitro by application of 0.5 mg ml −1 LPC (Sigma-Aldrich) for 18-20 h, which was subsequently washed off in fresh medium for 10 min; comparisons were made with vehicle (PBS)-treated explants. Necrostatin-1 (10 µM; Sigma-Aldrich) or vehicle (dimethylsulfoxide; 1:1,000) was supplemented to media on LPC treatment and in each subsequent media change before fixation. Propidium iodide (25 µg ml -1 ; Sigma-Aldrich) was supplemented to the medium for the last 1 h before fixation, and explants were washed thrice in PBS before fixation in the dark. Explants were fixed in 4% paraformaldehyde (PFA) for 10 min. Each n is the average of three explants from 1 litter, with 3-5 litters per time point/condition. Neutralizing antibody against IFNAR2 (R&D Systems, AF1083; 5 µg ml −1 final concentration), or goat isotype IgG control of matched concentration, was applied to explants up to 1 and 7 dpl.
Immunofluorescent staining of explant cultures. Explants were permeabilized and blocked for 1 h in 5% horse serum and 0.3% Triton X-100 in PBS, and primary antibodies were applied for two nights overnight at 4 °C in a humid chamber. Primary antibodies used include rat anti-CD68 (Abcam, ab53444, 1: 100), rabbit anti-IBA-1 (Wako Chemicals, 019-19741, 1:50), goat anti-PU.1 (Santa Cruz Biotechnology, sc5949, 1:100), mouse anti-iNOS (BD Biosciences, 610329, 1:100), goat anti-Arginase-1 (Santa Cruz Biotechnology, sc18355, 1:50), rabbit anti-RIPK3 (Novus Biologicals, NBP1-77299, 1:100), rat anti-MLKL (Merck-Millipore, MABC604, 1:100), rabbit anti-cleaved Caspase-3 (BD Pharmingen, 559565, 1:100), mouse anti-cleaved Caspase-1 (Santa Cruz Biotechnology, sc22165, 1:100), rat anti-MBP (AbD Serotec, MCA409S, 1:250), chicken anti-neurofilament heavy chain (Encor Biotechnology, CPCA-NF-H, 1:10,000), mouse anti-Nestin (Abcam, ab6142, 1:100), rabbit anti-Olig2 (Merck, AB9610, 1:100), rabbit anti-GFAP (DAKO, Z0334, 1:500), mouse anti-NeuN (Merck-Millipore, MAB377, 1:100), rabbit anti-Musashi-1 (Abcam, ab52865, 1:100), mouse anti-Sox-2 (Abcam, ab171380, 1:100) and mouse anti-P-Y701 (Abcam, ab29045, 1:100). Subsequent to washes in PBS, fluorescently conjugated secondary antibodies were applied for 2 h at 20-25 °C in a humid chamber (antigoat IgG (A21432, A11055), anti-rabbit IgG (A11034, A21206, A10042, A11011), anti-rat IgG (A21434, A11006, A21247), anti-mouse IgG (A31570, A21235, A31571, A21042) and anti-chicken IgG (A11039)) (1:1,000, Invitrogen). Explants were counterstained with Hoechst, mounted on slides and coverslipped with Fluoromount-G (Southern Biotech). Z-stacks of explants were acquired with an Olympus spinning disk confocal microscope using a ×20 objective with Slidebook 6 software. Remyelination in explants was assessed by determining area of colocalization of MBP and NF-H signal normalized to NF-H pixel counts using Volocity 6.3 software (Perkin Elmer).
Live imaging of explant cultures. An insert with cultured explants was adhered by the feet to a single 4-cm petri dish with molten wax and left briefly to dry. Medium was first pipetted into the petri dish to diffuse under the mesh then gently pipetted onto the surface of mesh. Z-stacks were acquired using a ×20 wet-immersion objective on the Olympus spinning disk confocal microscope using Slidebook 6 software, incubated at 37 °C (high humidity) and 5% CO 2 . Large Z-stacks were acquired to ensure that the explant was always in focus, and maximum projection videos are shown ( Supplementary Videos 1 and 2) .
Focal demyelinating lesion induction. Ten-week-old male C57Bl/6J mice were anaesthetized with isoflurane before being stereotaxically injected with 2 μl 1% lysophosphatidyl choline (LPC; v/v) into the corpus callosum. Control mice underwent the same procedure with a sham injection. Mice were allowed to recover before killing by perfusion-fixation at 3, 7 and 10 dpl with 4% PFA for immunofluorescence, or 3.8% sodium citrate in PBS for flow cytometric analysis. The former were post-fixed overnight with 4% PFA, cryoprotected in sucrose and cryosectioned at 12-µm thickness. A minimum of three animals were analyzed per time point.
LNC formulation. Kolliphor HS15 (0.169 g), Lipoïd (0.15 g; Lipoid Gmbh), NaCl (0.0178 g), Labrafac (0.2056 g; Gattefosse SA) and water (0.592 g) were mixed under gentle magnetic stirring at 50 °C for 5 min. The solution was progressively heated (90 °C) and cooled (60 °C) three times. During the last cooling, cold water (2.408 g at 4 °C) was added at 72-74 °C under high-speed stirring. Necrostatin-1-loaded LNCs were prepared by adding 25.9 µl necrostatin-1 stock solution (30 mg ml −1 in dimethylsulfoxide) during the last cooling of LNC preparation. Control LNCs were prepared following the same protocol using dimethylsulfoxide. Fluorescent LNCs (DiD; ThermoFisher) were prepared with the same protocol using 220 µl DiD solution (1 mg ml −1 in absolute ethanol). The nanoparticles were filtered on a sterile 0.2-µm filter and stored at 4 °C until further use. The concentration of necrostatin-loaded LNC stock solution was 1 mM necrostatin-1 and 126 mg ml −1 nanoparticles. Size, zeta (ζ)-potential and PDI of nanoparticles were measured using a Malvern Zetasizer Nano ZS (Malvern Instruments) (N = 3, n = 3). For the measurement of size and PDI, samples were diluted 1/100 (v/v) in water. For the measurement of ζ-potential, samples were diluted 1/100 (v/v) in NaCl 10 mM. The encapsulation efficiency of necrostatin-1 was calculated using the following formula:
Necrostatin-1 was extracted from necrostatin-1 LNC by dissolution in methanol at a ratio of 1:20 (v/v) ('Necrostatin-1 total'). Necrostatin-1 was quantified by reversed-phase HPLC (Waters) with a Macherey-Nagel 125/4 Nucleodur 100-5 C18 column. A gradient mobile phase was composed of 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B). The gradient was set as follows: for the first 2 min, the gradient was set at 80% A and 20% B. Then, A decreased to 60% for the following 3 min, and for the last 2 min A decreased to 20%. The flow was set for both solutions at 1 ml min −1 with a volume of injection of 20 μl, and the detection wavelength was set at 269 nm. To determine the percentage of non-encapsulated necrostatin-1, necrostatin-1 LNCs were centrifuged in a VIVAPSIN 500 with a membrane that possessed a 30-KDa MWCO at 13,000g for 10 min, and the filtered solution was collected and quantified by reversed-phase HPLC. The properties of the LNCs were as follows: (1) necrostatin-1 LNCs: 54.2 nm/0.05 PDI/−2.0 mv ζ− potential/263.8 µg ml −1 /100% encapsulation efficiency, (2) dimethylsulfoxide LNCs: 56.4 nm/0.06 PDI/−1.7 mv ζ−potential/0.86% (v/v) concentration, and (3) DiD LNCs: 64.1 nm/0.08 PDI/−1.8 mv ζ−potential/14.7% (v/v) concentration. LNCs were stereotaxically injected into the corpus callosum of adult mice at the time of lesioning, and mice were killed at 3 or 10 dpl. The 3D surface view in Slidebook 6 was used for 3D rendering to visualize DiD-LNC localization.
Microglia isolation and RNA extraction/sequencing. Lesioned corpus callosum of 8-12-week-old male C57Bl6J mice was homogenized using a 2-ml Dounce and filtrated (250-µm filter; Pierce). Following a spin at 600g for 5 min (with brake), cells were resuspended in 100% fetal bovine serum (FBS) and 33% Percoll (1:10), overlaid with 1 ml 10% FBS and spun for 15 min at 800g at 4 °C without brake. The cell pellet was washed in FACS buffer and spun for 10 min at 600g at 4 °C, and incubated in anti-mouse CD16/32 Fc-block (Clone 93, BioLegend, 1:200) on ice for 10 min. Fluorescently conjugated antibodies CD11b-PeCy7 (Clone M1/70, Invitrogen, 1:100), CD45-BV605 (Clone 30D11, BioLegend, 1:200), Ly6G-PerCP Cy5 (Clone 1A8, BioLegend, 1:200) and CD3-APC (Clone 17A2, BioLegend, 1:200) were applied on ice for 30 min. Following centrifugation and filtration (30 μm), cells were sorted by flow cytometry into FBS-coated Eppendorf tubes on ice (BD FACSAria Fusion, 100-µm nozzle). Use of differential CD45 expression (on the logarithmic scale) to distinguish between microglia (lo) and infiltrating monocytederived macrophages (hi) in white matter injury has been previously validated using transgenic reporters and bone marrow chimeras. Cells were spun at 800g for 5 min, resuspended in RLT Plus buffer with β-mercaptoethanol and centrifuged at 10,000 r.p.m. for 2 min in QIAshredder tubes (Qiagen). RNA was extracted using the AllPrep DNA/RNA/miRNA kit (Qiagen) as per the manufacturer's instructions, and quantity/quality analyzed using the Bioanalyser 2100 (Agilent) and RNA 6000 Pico kit (Agilent) as per the manufacturer's instructions. Complementary DNA production/library preparation was performed using the NuGEN Ovation RNAseq System v2 kit (NuGEN) by BGI (Hong Kong). End Repair Mix was added to the amplified cDNA and incubated at 20 °C for 30 min. AxyPrep Mag PCR Clean-up
Nature NeuroSCieNCe streptomycin (v/v). Treatment included LPC (0.5 mg ml -1 ), (Sigma-Aldrich) before fixation with 4% PFA (Sigma) for 10 min. Cells were blocked for 1 h and incubated with primary antibodies at room temperature for 1 h, for 1 h at room temperature before counterstaining with Hoechst, mounting onto slides and coverslipping with Fluoromount-G.
Immunofluorescent staining of cuprizone tissue. Paraffin-embedded sections of tissue from cuprizone-fed mice underwent deparaffinization using Histoclear (2 × 10 min) and a gradient of ethanol concentrations, each for 5 min in the following order: 2 × 100%, 1 × 95%, 1 × 70% and 1 × 50%, before being washed in Tris-buffered saline (TBS) for 3 × 5 min washes. Slides were then placed in Vector Unmasking Solution under high heat and pressure for 20 min before a final TBS wash. Slides were permeabilized and blocked for 1 h (5% horse serum and 0.3% Triton X-100 in PBS) before incubation with primary antibodies overnight at 4 °C in a humid chamber. Microglia/macrophages were detected with rat anti-CD68 (Abcam, Ab53444, 1: 100) and cell death was assessed using rabbit anti-RIPK3 (Novus Biologicals, NBP1-77299, 1:100) and rat anti-MLKL (Merck-Millipore, MABC604, 1:100). Following washes in PBS, fluorescently conjugated secondary antibodies were applied (Invitrogen, 1:1,000). Slides were counterstained with Hoechst and coverslipped with Fluoromount-G (Southern Biotech). Images were acquired with an Olympus spinning disk confocal microscope using a ×60 objective with Slidebook 6 software. Three animals were analyzed per time point.
Human tissue. Post-mortem tissue from patients with multiple sclerosis and controls that died of non-neurological causes were obtained via a UK prospective donor scheme with full ethical approval from the UK Multiple Sclerosis Tissue Bank (MREC/02/2/39) and their use was in accord with the terms of the informed consents. Diagnosis of multiple sclerosis was confirmed by neuropathological means by F. Roncaroli (Imperial College London) and clinical history was provided by R. Nicholas (Imperial College London). Snap-frozen unfixed tissue blocks (2 × 2 × 1 cm 3 ) were cut at 10 μm and stored at −80 °C. Lesions were classified according to the International Classification of Neurological Disease using Luxol Fast Blue staining and CD68 + immunoreactivity. Following washes in 0.1% Tween-20 (v/v) in TBS, sections were microwaved in Vector Unmasking Solution for 10 min, washed once, and endogenous phosphatase and peroxidase activity blocked for 5 min (Bloxall, Vector). Tissue was incubated with primary antibodies in a humid chamber overnight. Sections were then washed in TBS and stains visualized by Vector Blue substrate kit according to the manufacturer's instructions (maximum 15 min). For co-staining, sections were washed thrice and re-blocked to quench any remaining phosphatase activity (Bloxall, Vector) before application of primary antibody, then developed using Vector Red substrate kit according to the manufacturer's instructions (maximum 15 min). Following washes in water, the sections were counterstained with Hoechst and coverslipped with Fluoromount-G. Primary antibodies used include goat anti-CD68 (Santa Cruz Biotechnology, sc7082, 1:100), mouse anti-Nestin (Santa Cruz Biotechnology, sc23927, 1:100), goat anti-PU.1 (Santa Cruz Biotechnology, sc5949, 1:100), rat anti-MLKL (MerckMillipore, MABC604, 1:100) and rat anti-RIPK3 (Novus Biologicals, NBP1-77299, 1:100). Entire tissue sections were imaged using a Zeiss AxioScan Z.1 SlideScanner, and digital lesion maps were prepared for each tissue in Zeiss Zen2 software using Luxol Fast Blue-stained sections. Fields of 360 × 360 μm 2 were counted per lesion and counts were multiplied to determine density of immunopositive cells per mm 2 . For quantification of Nestin + PU.1 + cells, staining with blood vessel morphology was excluded from counts.
Statistics. Details on experimental design and reagents can be found in the Life Sciences Reporting Summary. For animal experiments, power was calculated by two-sided 95% confidence interval using the normal approximation method using OpenEpi software, and gave 88-100% power for all experiments. Animals were randomly selected for experimental groups, and littermates were compared for all treatment groups. All manual cell counts for explant cultures, in vivo lesioned tissue and multiple sclerosis tissue were performed in a blinded manner. Data are represented as mean ± s.e.m. from a minimum of three mice (in vivo experiments) or litters (explants). Data distribution was assessed using the Kolmogorov-Smirnov test. Data were statistically analyzed by two-tailed Student's t-test or MannWhitney test for ≤2 comparisons, one-sample t-test for analysis of normalized data or comparison to sham, and either Kruskal-Wallis test with Dunn's Multiple Comparison post-test or 1-way analysis of variance (ANOVA) with Sidak's posttest (for select comparisons between groups) for ≥3 comparisons. P values of ≤0.05 were considered statistically significant at a confidence interval of 95%. Data handling and statistical processing were performed using Microsoft Excel and GraphPad Prism 7 and 8 Software. Diagrams were created with BioRender software.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding author on request. The RNA sequencing data discussed in this Kit (Axygen) was used to purify the end-repaired DNA, which was then combined with A-tailing Mix (Enzymatic) and incubated at 37 °C for 30 min. Adapters (Invitrogen) were ligated to the adenylated 3′ ends DNA, and incubated at 16 °C for 16 h. Insert size was used to select the adapter-ligated DNA fragments. Several rounds of PCR amplification with PCR Primer Cocktail (Invitrogen) and PCR Master Mix (New England Biolabs) were performed to enrich the adapter-ligated DNA fragments to produce the final library, purified using AxyPrep Mag PCR Clean-up Kit. The final library average molecule length was determined using the Bioanalyser 2100 using the DNA 1000 kit (Agilent) and was quantified by real-time quantitative PCR (qPCR) (TaqMan probe). cBot (Illumina) was used to amplify the libraries to generate the cluster on the Flow Cell (HiSeq 4000, Illumina). An average of 40 million clean 100 paired-end reads (read lengths approximately 100 base pairs) were achieved per sample, with >91% uniquely mapped reads. Data were processed to remove adapters and low-quality reads from raw reads.
Bioinformatics. Raw data analysis was carried out by Fios Genomics (Edinburgh, United Kingdom). RNAseq data were preprocessed and aligned to the mouse genome (GRCm38) using STAR aligner, and the numbers of mapped read-pairs per gene were quantified based on the GENCODE v.M12 annotation. A total of six samples (three per time point) were quality control analyzed using the 'array Quality Metrics' package in Bioconductor. Data were normalized using trimmed mean of M values and transformed using VOOM to log 2 -counts per million, with associated precision weights. Comparisons were undertaken using linear modeling using Limma package in Bioconductor to determine differentially expressed genes (P < 0.05); empirical Bayesian analysis for log 2 fold change was applied. Differentially expressed genes were used for functional enrichment analysis by investigation of KEGG pathways (P < 0.05), Gene Ontology terms (P < 0.05), Venny 2.1 21 and IPA (P < 0.05). .
Immunofluorescent staining of in vivo focal lesions. Sections of frozen tissue were air dried for 15 min before being permeabilized and blocked for 1 h (5% horse serum and 0.3% Triton X-100 in PBS), then incubated with primary antibodies overnight at 4 °C in a humid chamber. Primary antibodies used include rabbit anti-Tmem119 (Abcam, ab209064, 1:100), rat anti-CD68 (Abcam, As53444, 1:100), rabbit anti-IBA-1 (Wako Chemicals, 019-19741, 1:50), rabbit anti-RIPK3 (Novus Biologicals, NBP1-77299, 1:100), rat anti-MLKL (Merck-Millipore, MABC604, 1:100), mouse anti-iNOS (BD Bioscience, 610329, 1:100), goat anti-Arginase-1 (Santa Cruz Biotechnology, sc18355, 1:50), mouse anti-Nestin (Abcam, ab6142, 1:100), mouse anti-MAG (EMD Millipore, MAB1567, 1:100), rat anti-MBP (AbD Serotec, MCA409S, 1:250), rabbit anti-Ki67 (EMD Millipore, AB9260, 1:100), mouse anti-Olig1 (EMD Millipore, MAB5540, 1:100), mouse anti-P-Y701 (Abcam, ab29045, 1:100) and rabbit anti-IFNAR2 (Abcam, ab56070, 1:100). Subsequent to washes in PBS, fluorescently conjugated secondary antibodies were applied for 2 h at 20-25 °C in a humid chamber (anti-rabbit IgG (A11034, A21206, A10042, A11011) and anti-rat IgG (A21434, A11006, A21247) all at a concentration of 1:1000 (all from Invitrogen)). Slides were counterstained with Hoechst and coverslipped with Fluoromount-G (Southern Biotech). Images were acquired with an Olympus spinning disk confocal microscope with ×20 or ×60 objectives with Slidebook software. Percentage of IBA-1/Nestin or Tmem119/CD68 co-localization was measured by determining area of co-localization relative to total IBA-1 or CD68 pixel counts, respectively, using Volocity 6.3 software (Perkin Elmer). MAG intensity within lesions was quantified using Adobe Photoshop CS4 with respective background intensity outside the lesion subtracted.
Flow cytometry. Focal demyelinated lesions of the corpus callosum of 8-12-weekold C57Bl6J male mice were dissected out and homogenized with a 2 ml Dounce. A Percoll (Sigma-Aldrich) gradient was used to isolate cells from myelin debris. Samples were blocked with Fc-block (LEAF-purified anti-mouse CD16/32 (BioLegend, 101321)), then incubated with fluorochrome-conjugated antibodies CD11b-PeCy7 (eBioscience, 25-0112-82, 1:100) and CD45-BV605 (BioLegend, 103139, 1:100) for 30 min on ice, followed by incubation with 'FITC Annexin-V apoptosis detection kit with 7-AAD' for 15 min at room temperature (BioLegend, 640922, 1:20) . Following washes in buffer, samples were run on the BD LSR Fortessa (6 laser) analyzer, and analyzed using FlowJo version 9/10 software (FlowJo).
Primary microglia cultures. Microglia were derived from mixed glial cultures of P0-P3 Sprague-Dawley rats of both sexes by differential adhesion, as previously described 
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Software and code
Policy information about availability of computer code Data collection Slidebook 6 software was used for 3D rending, confocal imaging and live-imaging. FACS and flow cytometry data was acquired using FlowJo version 9 and 10 software. Human tissue was acquired using the Zeiss Zen2 software.
Data analysis
Remyelination index was quantified using Volocity 6.3 software. Bioinformatics on RNA sequencing data was carried out using STAR aligner, Bioconductor (limma package), QIAGEN Ingenuity Pathway Analysis. Real time PCR data was analysed using CFX manager. MAG intensity was quantified using Adobe Photoshop CS4. Data handling was performed using Microsoft Excel and statistical analysis was performed using GraphPad prism 7 and 8. Power calculations were performed using OpenEpi website (www.openepi.com).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability RNA sequencing data is available on GEO as the series GSE118450, accession numbers are GSM3330371, GSM3330372, GSM3330373, GSM3330374, GSM3330375, GSM3330376. All Log2 fold changes are available as Supplementary 
